In order to better characterize the factors that influence the specific phenotypes associated with GBA and LRRK2 PD as well as those that might contribute to disease risk, we assessed the prevalence of MS and its’ different components among genetically determined patients with PD and non-manifesting carriers of mutations in the LRRK2 or GBA genes (NMC) and correlated PD phenotype and future probability for developing PD with the presence of MS. This evidence concerns the gene GBA1 and myeloid sarcoma.